Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Nov 24;4(22):5745-5754.
doi: 10.1182/bloodadvances.2020003073.

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients

Adam S Nelson  1   2 , Daria Heyenbruch  3 , Jeremy D Rubinstein  1   2 , Anthony Sabulski  1   2 , Sonata Jodele  1   2 , Shawn Thomas  1 , Carolyn Lutzko  4 , Xiang Zhu  4 , Thomas Leemhuis  3 , Jose A Cancelas  3   4 , Michael Keller  5 , Catherine M Bollard  5 , Patrick J Hanley  5 , Stella M Davies  1   2 , Michael S Grimley  1   2
Affiliations
Clinical Trial

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients

Adam S Nelson et al. Blood Adv. .

Abstract

BK polyomavirus (BKPyV) infection is a major complication of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). Treatment options are limited, poorly effective, and have significant toxicities. Cellular therapy using T cells directed against BKPyV is an emerging therapy, and we report efficacy in controlling BKPyV-associated disease in highly immunocompromised patients. Virus-specific T cells (VSTs) against BKPyV were manufactured using either blood from the patient's stem cell donor (donor-derived VSTs) or from unrelated donors (third-party VSTs). VSTs were used to treat BKPyV in 38 HSCT recipients and 3 SOT recipients between June 2017 and December 2019. Overall response rate was 86% in patients treated for BK viremia, 100% in patients treated for hemorrhagic cystitis, and 87% in patients treated for both BK viremia and hemorrhagic cystitis. No infusional toxicity, de novo graft-versus-host disease, or rejection of the organ occurred attributable to the VST infusion. BKPyV-specific immune responses were demonstrated by interferon-γ production by peripheral blood mononuclear cells postinfusion in response to BKPyV antigens. VSTs are a safe and potentially effective strategy to treat BKPyV and associated symptoms in recipients of HSCT and SOT. Cellular therapy should be considered for all patients with BKPyV and underlying immune suppression at risk of complications. This trial was registered at www.clinicaltrials.gov as #NCT02532452.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: C.M.B. is on the advisory board for Cellectis and is on the scientific advisory boards for Catamaran Bio and Mana Therapeutics with stock and/or ownership, is on the board of directors for Caballeta Bio with stock options, and has stock in Neximmune and Torque Therapeutics. P.J.H. is a cofounder and on the board of directors of Mana Therapeutics and has filed intellectual property related to virus-specific T cells. S.M.D. has a US pending patent application under review, received research support from Alexion Pharmaceuticals, and consultancy from Novartis. S.J. has a US pending patent application under review and received travel support and consultancy fees from Omeros (unrelated to this work). The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Response to VSTs. (A) Response to donor-derived BKPyV-VST flowchart. (B) Response to third-party BK-VST flowchart.
Figure 2.
Figure 2.
Characteristics of the cellular and viral response. (A) The median number of BKPyV-specific T cells pre- and post-VST infusion. Interferon-γ response and corresponding viral PCR in patients who require 1 VST infusion (B), in a patient requiring multiple VST infusions (C), and in 1 patient who did not respond to VST infusion (D).
See this image and copyright information in PMC

References

    1. Hirsch HH, Knowles W, Dickenmann M, et al. . Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488-496. - PubMed
    1. Bedi A, Miller CB, Hanson JL, et al. . Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol. 1995;13(5):1103-1109. - PubMed
    1. Haines HL, Laskin BL, Goebel J, et al. . Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(10):1512-9151. doi: 10.1016/j.bbmt.2011.02.012. PubMed PMID: 21385622. - PubMed
    1. Cesaro S, Dalianis T, Hanssen Rinaldo C, et al. ; ECIL-6 Group. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73(1):12-21. 10.1093/jac/dkx324 - PubMed
    1. Erard V, Kim HW, Corey L, et al. . BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood. 2005;106(3):1130-1132. doi: . PubMed PMID: 15845896; PubMed Central PMCID: PMCPMC1895165. - PMC - PubMed

Publication types

Associated data

LinkOut - more resources